Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

590 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
13-valent pneumococcal conjugate vaccine given with meningococcal C-tetanus toxoid conjugate and other routine pediatric vaccinations: immunogenicity and safety.
Martinón-Torres F, Gimenez-Sanchez F, Gurtman A, Bernaola E, Diez-Domingo J, Carmona A, Sidhu M, Sarkozy DA, Gruber WC, Emini EA, Scott DA; 3007 Study Group. Martinón-Torres F, et al. Among authors: sidhu m. Pediatr Infect Dis J. 2012 Apr;31(4):392-9. doi: 10.1097/INF.0b013e31824b972b. Pediatr Infect Dis J. 2012. PMID: 22301472 Clinical Trial.
Pneumococcal conjugate vaccine-elicited antibody persistence and immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously vaccinated with 4 doses of either 7-valent or 13-valent pneumococcal conjugate vaccine.
Quinet B, Laudat F, Gurtman A, Patterson S, Sidhu M, Gruber WC, Scott DA. Quinet B, et al. Among authors: sidhu m. Pediatr Infect Dis J. 2014 Oct;33(10):1065-76. doi: 10.1097/INF.0000000000000459. Pediatr Infect Dis J. 2014. PMID: 25093973 Clinical Trial.
13-Valent pneumococcal conjugate vaccine (PCV13) in children partially immunized with 7-valent pneumococcal conjugate vaccine (PCV7): a phase 3, open-label trial.
Silfverdal SA, Flodmark CE, Rombo L, Tansey SP, Sidhu M, Trammel J, Emini EA, Gruber WC, Scott DA, Gurtman A; 3012 study group. Silfverdal SA, et al. Among authors: sidhu m. Vaccine. 2013 Feb 18;31(9):1284-92. doi: 10.1016/j.vaccine.2012.12.066. Epub 2013 Jan 7. Vaccine. 2013. PMID: 23306363 Clinical Trial.
Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older.
Frenck RW Jr, Fiquet A, Gurtman A, van Cleeff M, Davis M, Rubino J, Smith W, Sundaraiyer V, Sidhu M, Emini EA, Gruber WC, Scott DA, Schmoele-Thoma B; B1851020 Study Group. Frenck RW Jr, et al. Among authors: sidhu m. Vaccine. 2016 Jun 24;34(30):3454-62. doi: 10.1016/j.vaccine.2016.04.093. Epub 2016 May 5. Vaccine. 2016. PMID: 27155493 Clinical Trial.
Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine in Older Adults With and Without Comorbidities in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA).
van Deursen AMM, van Houten MA, Webber C, Patton M, Scott DA, Patterson S, Sidhu M, Drews W, Gruber WC, Emini EA, Grobbee DE, Bonten MJM, Sanders EAM. van Deursen AMM, et al. Among authors: sidhu m. Clin Infect Dis. 2017 Sep 1;65(5):787-795. doi: 10.1093/cid/cix419. Clin Infect Dis. 2017. PMID: 29017280 Clinical Trial.
590 results